mk-8527
Small moleculeexperimental
Clinical trial activity
12 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
9
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started Oct 1, 2018 (NCT03615183)
Timeline
Indications
Mechanism of action
- Reverse transcriptaseINHIBITOR
Reverse transcriptase inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07071623 | Phase 3 | Nov 10, 2025 | Merck |
| NCT07025551 | Phase 1 | Sep 19, 2025 | Merck |
| NCT07063238 | Phase 1 | Aug 12, 2025 | Merck |
| NCT07044297 | Phase 3 | Jul 31, 2025 | Merck |
| NCT06826989 | Phase 1 | Mar 19, 2025 | Merck |
| NCT06816043 | Phase 1 | Feb 21, 2025 | Merck |
| NCT06580587 | Phase 1 | Nov 25, 2024 | Merck |
| NCT06295796 | Phase 1 | Jun 20, 2024 | Merck |
| NCT06045507 | Phase 2 | Nov 8, 2023 | Merck |
| NCT06783192 | Phase 1 | Aug 14, 2023 | Merck |
| NCT05494736 | Phase 1 | Nov 11, 2022 | Merck |
| NCT03615183 | Phase 1 | Oct 1, 2018 | Merck |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 12 | 12 | 3 | 2018 |
1 organizations
Page 1 / 1